We are proudly backed by a strong group of global investors focused on improving healthcare outcomes and giving sponsors a better CRO choice.
Our best-in-class global institutional investment partners, including a leading US university and a leading global asset manager, support our unique vision and endorse our competitive differentiation, helping us on our mission to reach patients and improve lives.
Caidya is the trade name of dMedClinical Co. Ltd. and its holdings. Clinipace, Inc. is one company in the Caidya group of companies. Clinipace, Inc. is owned, operated, managed, and controlled by dMedClinical Co. Ltd., a privately held company, whose investors include entities located in the People’s Republic of China (PRC), and which may be subject to PRC laws and regulations that differ from those of the United States. dMedClinical’s investor group are part of a best-in-class shareholder group which includes leading global venture capital and healthcare specialists.
Ready to elevate your clinical development experience? Learn more about how our personalized solutions can help you enable better healthcare outcomes.
Explore our news and updates as we liberate the clinical research process.
MORRISVILLE, N.C., November 9, 2022 – Caidya, the multi-therapeutic clinical research organization (CRO) focused on delivery excellence and an elevated customer experience, announced today the appointment ...
SHANGHAI and MORRISVILLE, N.C., October 3, 2022 – dMed | Clinipace, ...
SHANGHAI, CHINA and MORRISVILLE, NORTH CAROLINA, USA, April 28, 2021 – ...